A Phase 3 interventional study of Aspirin in Fetal Growth Restriction, Fetal Growth Retardation and Intrauterine Growth Restriction, sponsored by Johns Hopkins University. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-16.
Sponsored by Johns Hopkins University · Phase 3, Interventional, and Treatment
The purpose of this investigation is to evaluate the ability of maternal aspirin (ASA) therapy to prevent preterm birth for fetal indications prior to 32 weeks gestation in women with early onset Fetal Growth Restriction (FGR). Aspirin is a commonly used medication that blocks blood platelets from clumping. Aspirin crosses the placenta in a dose dependent mode. There is preliminary evidence in smaller studies that aspirin can block fetal platelet clumping and, therefore, slow down the progression of placental disease under specific circumstances. The optimal time for aspirin to work is when the fetus' placental dysfunction is still mild. The goal of this research study is to show if fetuses that receive aspirin through maternal intake at a dose shown to affect fetal platelet aggregation will be less likely to deliver before 32 weeks for fetal deterioration. The outcomes of patients that receive aspirin will be compared to women that receive standard FGR management but do not take any aspirin. The decision if a study participant receives aspirin or not will be randomly picked. Such a research study is called a randomized controlled trial.
Early onset FGR requiring preterm delivery by 32 weeks gestation complicates 1-5% of pregnancies and is an important health problem. Over 60% of children have long-term health consequences after being delivered for early onset FGR. There is no prenatal treatment for fetal growth restriction. The current management of FGR consists of fetal surveillance to detect a decline in the baby's health and deliver when this can be safely done. In a large number of early onset FGR, premature delivery is required to prevent the fetus from becoming more compromised or even dying in the womb.
Placental dysfunction leading to early onset FGR is characterized by changes to the blood vessels of the placenta, leading to a decline in the amount of blood flow to the placenta. The arteries that run in the umbilical cord of the fetus (umbilical arteries) are important for nutrient exchange between the fetal and placental circulation. Many fetuses with early onset FGR have elevated resistance in the blood vessels entering the placenta. This results in decreased blood flow in the umbilical artery (UA). The blood flow in the umbilical artery is evaluated by a specialized ultrasound technique called Doppler ultrasound. Doppler ultrasound of the umbilical arteries examines the blood flow to see if there is evidence of abnormal blood flow into the placenta. When the amount of blood flow at the end of every pulse decreases, it is classified as elevated UA blood flow resistance. When the blood flow briefly pauses at the end of each pulse, this is called absent end-diastolic velocity (AEDV) or UA AEDV. When the blood flow reverses at the end of each pulse, this is called reversed end-diastolic velocity (UA REDV). In fetuses with elevated UA blood flow, the placenta can usually supply enough nutrients and oxygen for at least 9 weeks. After that time, delivery is typically required. The worsening of blood flow to UA AEDV, or even UA REDV, increases the risk for fetal deterioration and preterm birth within the next 2-6 weeks. Approximately, 80% of early onset FGR fetuses progress to UA AEDV, or even UA REDV, and then require delivery by 32 weeks. There is no treatment that can stop this progression which is of critical importance in determining how much time is left for the fetus before delivery will be necessary.
264 studies on the registry are indexed under Fetal Growth Retardation; 66 are open to participants now.
Browse Fetal Growth Retardation studies →Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Receives standard of care and intervention.
Drug: Aspirin
Receives standard of care (SOC), only
Two tablets daily with dinner
Also known as: acetylsalicylic acid (ASA)
Number of fetuses delivered for non-reassuring fetal status prior to 32+0 week's gestation
To determine the frequency of delivery prior to 32+0 weeks' gestation for abnormal fetal surveillance parameters.
Time frame: From randomization until birth, up to 38 weeks gestation
Change in UA Doppler index
UA Doppler index is assessed at enrollment (baseline) and weekly. Qualitative changes in UA Doppler index are measured as presence, absence or reversal of end-diastolic velocity.
Time frame: Baseline and weekly, up to 38 weeks gestation
Change in amniotic fluid index (AFI)
Amniotic fluid index, measured with amniotic fluid volume \[in centimeters (cm)\] will be assessed at enrollment (baseline) and weekly. Oligohydramnios is an AFI ≤ 5 cm or a maximum vertical pocket (MVP) pocket ≤ 2 cm.
Time frame: Baseline and weekly, up to 38 weeks gestation
Change in fetal heart rate decelerations
Fetal heart rate decelerations \[in milliseconds (ms)\] is assessed at enrollment (baseline) and weekly to bi-weekly. Heart rate variability increases with gestational age. After 29 weeks gestation, 4.0 ms and 3.0 ms meet criteria for reduced or very low short-term variation (STV) respectively. Before 29 weeks gestation, an STV \<3.5 ms is considered reduced and \<2.6 ms as very low.
Time frame: Baseline and weekly to bi-weekly, up to 38 weeks gestation
Change in biophysical profile score
Biophysical profile score is assessed at enrollment (baseline) and weekly to bi-weekly. The biophysical profile (BPP) combines a nonstress test (NST) with an ultrasound to evaluate a baby's heart rate, breathing, movements, muscle tone and amniotic fluid level. Each gives a score between 0 and 2 and are added up for a total maximum score of 10. A score of 8 or 10 is considered normal, while a score below 8 usually requires further evaluation or delivery of the baby.
Time frame: Baseline and weekly to bi-weekly, up to 38 weeks gestation
Gestational age at delivery
Gestational age at delivery measured in weeks.
Time frame: At time of birth, up to 38 weeks gestation
Birthweight percentile at delivery
Birthweight percentile will be assessed at the time of delivery.
Time frame: At time of birth, up to 38 weeks gestation
Placental size at delivery
Placental size measured in grams at delivery.
Time frame: At time of birth, up to 38 weeks gestation
No study locations are listed for this record.
Plan to share: No
This study is withdrawn, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University